Misoprostol Dosing Recommendations
For labor induction, use 25 µg vaginal misoprostol every 3-6 hours or 20-25 µg oral solution every 2-6 hours, with the oral route resulting in fewer cesarean sections and lower hyperstimulation rates. 1
Labor Induction and Cervical Ripening
Preferred Dosing Regimens
Vaginal administration: 25 µg every 3-6 hours is effective for cervical ripening and labor induction, with the 4-hourly interval potentially more effective than 6-hourly dosing 2, 3
Oral administration: 20-25 µg every 2-6 hours is the preferred starting dose, resulting in fewer cesarean sections and lower rates of uterine hyperstimulation compared to vaginal administration 1
The 50 µg dose every 6 hours may be appropriate in select situations but carries significantly increased risk of uterine hyperstimulation and should be used cautiously 2
Route Comparison
Oral misoprostol probably results in fewer cesarean sections (RR 0.84) and less hyperstimulation with fetal heart rate changes (RR 0.69) compared to vaginal dinoprostone 1
Vaginal misoprostol achieves more vaginal deliveries within 24 hours (RR 0.82) but may increase uterine hyperstimulation risk 3
Oxytocin augmentation is more frequently needed with oral versus vaginal administration (RR 1.29) 1, 3
Critical Safety Monitoring
Continuous fetal heart rate and uterine activity monitoring is mandatory from 30 minutes to 2 hours after administration 2, 4
Monitor for uterine hyperstimulation, which occurs more frequently with 50 µg doses (35.86% vs 10.75% with 25 µg) 5
Absolute Contraindications
Previous Cesarean Delivery
Misoprostol is absolutely contraindicated in women with previous cesarean delivery due to catastrophic uterine rupture risk 2, 1, 6
Uterine rupture risk with misoprostol is 13%, compared to 1.1% with oxytocin and 2% with prostaglandin E2 1, 6
This contraindication extends to any prior uterine incision, which should be treated equivalently to cesarean delivery 6
Safe alternatives include transcervical Foley catheter (no reported rupture risk), oxytocin (1.1% rupture risk), or dinoprostone (2% rupture risk) 6
Postpartum Hemorrhage
Emergency Dosing
Rectal administration: 1000 µg (five 200 µg tablets) for postpartum hemorrhage unresponsive to oxytocin and ergometrine 7
Sustained uterine contraction typically achieved within 3 minutes of rectal administration 7
This represents an effective alternative to parenteral prostaglandins while awaiting carboprost 7
The FDA label specifies this is for hospital use only and outside the approved indication 8
Intrauterine Fetal Demise
Second Trimester
- High-dose vaginal suppositories may be used for second-trimester intrauterine fetal demise 2
Third Trimester
- Intravaginal misoprostol can be used for labor induction with third-trimester intrauterine fetal demise 2
IUD Placement (Cervical Priming)
Limited Indication
Misoprostol should NOT be used routinely for IUD placement due to limited efficacy and side effects 9
Consider only for failed previous placement or known cervical stenosis: 200 µg vaginal at 10 and 4 hours prior, or 400 µg vaginal 4 hours prior 9
The 400 µg dose decreases placement difficulty but increases postprocedure cramping, particularly in nulliparous patients 9, 4
Cost and Practical Advantages
Misoprostol costs $0.36-$1.20 per 100 µg tablet, compared to $65-$75 for dinoprostone gel or $165 for dinoprostone insert 2, 1
Stable at room temperature, eliminating refrigeration requirements unlike dinoprostone 2, 1
Multiple routes of administration (oral, vaginal, sublingual, buccal, rectal) provide flexibility 10, 11
Common Pitfalls to Avoid
Never use in women with scarred uterus - the 13% rupture risk is unacceptably high and potentially fatal 1, 6
Avoid 50 µg doses for routine labor induction due to excessive hyperstimulation (35.86% vs 10.75% with 25 µg) and postpartum hemorrhage risk (9.78% vs 2.15%) 5
Do not use calcium channel blockers concurrently, as they may worsen outcomes in certain conditions 12
In advanced liver failure, consider alternative induction methods as misoprostol requires hepatic metabolism for conversion to active form 1
Recognize that unsupervised use can lead to serious complications and teratogenicity 10